Clinical Trial

A Study in Healthy Men to Test How BI 1584862 is Processed in the Body

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to find out how BI 1584862 moves through and exits the body of healthy men. To do this, BI 1584862 is labelled using radioactive carbon (C-14) and using a non-radioactive, naturally occurring, stable isotope (C-13). The study will measure how much of the study medicine is recovered in urine and faeces after taking it by mouth. It will also look at how much of the study medicine enters the bloodstream when taken by mouth compared to a small dose given directly into the bloodstream. The study staff measures the amount of BI 1584862 and its broken-down parts in the blood, the urine, and the stool.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2026-01-02; most recent amendment 2026-06-22.
Status change: Active, Not Recruiting → Completed 2026-03-16
Status change: Recruiting → Active, Not Recruiting 2026-03-03
Status change: Not Yet Recruiting → Recruiting 2026-02-02
Trial Details
NCT Number NCT07336758
Lead Sponsor Boehringer Ingelheim
Conditions Healthy
Enrollment 8 participants
Start Date 2026-01-22
Primary Completion 2026-03-04 (estimated)
Study Completion 2026-03-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-23